Leading causes of castration-resistant prostate cancer

Area of Science:

• Oncology
• Urology
• Cancer Biology

Background:

• Prostate cancer (PCa) is the second leading cause of cancer-related death in men.
• The androgen receptor (AR) plays a critical role in PCa initiation and progression.
• Androgen deprivation therapy (ADT) is the standard treatment, effectively suppressing AR signaling initially.

Purpose of the Study:

• To review established mechanisms driving castration-resistant prostate cancer (CRPC).
• To identify and discuss emerging therapeutic targets for advanced PCa.
• To provide insights into overcoming ADT resistance in prostate cancer.

Main Methods:

• Literature review of widely accepted mechanisms of castration resistance.
• Analysis of current therapeutic strategies and their limitations.
• Exploration of potential novel therapeutic targets based on resistance pathways.

Main Results:

• ADT initially shrinks tumors but often leads to castration-resistant PCa (CRPC).
• Multiple mechanisms contribute to CRPC, including AR amplification, mutations, and alternative signaling pathways.
• Understanding these mechanisms is crucial for developing effective treatments.

Conclusions:

• Castration resistance is a major challenge in advanced prostate cancer treatment.
• Targeting specific resistance mechanisms offers promising therapeutic avenues.
• Further research into novel therapeutic targets is essential for improving patient outcomes.